Innovations Accelerate Vaccine Tender

Grant agreement ID 101007799Start date 1 September 2021End date 28 February 2027Overall budget 38 542 552 ObjectiveInno4Vac proposes an ambitious programme that will harness the latest advances in immunology disease modelling and modelling for tackling persistent scientific bottlenecks in vaccine development and for de-risking and accelerating this process. To reach this aim the project is divided into four interlinked subtopics. In Subtopic 1 artificial intelligence in combination with big data analysis and computational modelling will be used to build an open-access and cloud-based platform for in silico vaccine efficacy assessment and development. Subtopic 2 will develop new and improved controlled human infection models CHIM against influenza RSV and C. difficile that will enable early vaccine efficacy evaluation. Subtopic 3 will contribute to the development of cell-based human in vitro 3D models that resemble the in vivo situation of an infection at the mucosa and more reliably predict immune protection. These models will be combined with the development of related functional immune assays for clinically relevant surrogate endpoints. Finally Subtopic 4 will develop a modular one-stop computational platform for in silico modelling of vaccine bio-manufacturing and stability testing. In parallel to the scientific-technical work the partners will develop strategies and roadmaps for positioning the newly developed models in the regulatory framework and integrating them into pharmaceutical vaccine development. The overall workplan is underpinned by horizontal activities on coordinationmanagement and disseminationcommunication including data management and future sustainability.To achieve these ambitious objectives Inno4Vacc has assembled a multidisciplinary consortium from academic and research institutions industries regulatory bodies and vaccine RD alliances. This unique partnership brings together clinical immunological microbiological systems biology mathematical models and regulatory expertise and includes world-leaders in each respective field.